Dianthus Therapeutics, Inc. /DE/ Current Assets
Dianthus Therapeutics, Inc. /DE/ (DNTH) had Current Assets of $897.54 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:AssetsCurrent · last filed 2026-08-04
- 2026-06-30: Assets, Current $897.54M.
- 2026-03-31: Assets, Current $1.12B.
- 2025-12-31: Assets, Current $409.44M.
- 2025-09-30: Assets, Current $413.82M.
| Period end | Assets, Current | Assets, Current as first filed |
|---|---|---|
| 2026-06-30 | $897.54M 10-Q · filed 2026-08-04 | |
| 2026-03-31 | $1.12B 10-Q · filed 2026-05-05 | |
| 2025-12-31 | $409.44M 10-Q · filed 2026-08-04 | |
| 2025-09-30 | $413.82M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $263.61M 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $271.00M 10-Q · filed 2025-05-12 | |
| 2024-12-31 | $280.90M 10-K · filed 2026-03-09 | |
| 2024-09-30 | $287.49M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $365.69M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $380.93M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $177.45M 10-K · filed 2025-03-11 | |
| 2023-09-30 | $191.45M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $78.64M 10-Q · filed 2023-08-03 | |
| 2023-03-31 | $83.44M 10-Q · filed 2023-05-15 | |
| 2022-12-31 | $82.03M 10-K · filed 2024-03-21 | $115.60M 10-K · filed 2023-03-23 |
| 2022-09-30 | $132.10M 10-Q · filed 2022-11-03 | |
| 2022-06-30 | $142.04M 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $160.24M 10-Q · filed 2022-05-16 | |
| 2021-12-31 | $9.39M 8-K · filed 2023-12-21 | $180.69M 10-K · filed 2022-03-08 |
| 2021-09-30 | $196.47M 10-Q · filed 2021-11-04 | |
| 2021-06-30 | $210.19M 10-Q · filed 2021-08-05 | |
| 2021-03-31 | $135.10M 10-Q · filed 2021-05-06 | |
| 2020-12-31 | $151.53M 10-K · filed 2022-03-08 | |
| 2020-09-30 | $164.27M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $179.88M 10-Q · filed 2020-08-06 | |
| 2020-03-31 | $133.13M 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $149.84M 10-K · filed 2021-03-03 | |
| 2019-09-30 | $165.23M 10-Q · filed 2019-11-13 | |
| 2019-06-30 | $183.01M 10-Q · filed 2019-08-08 | |
| 2019-03-31 | $135.08M 10-Q · filed 2019-05-09 | |
| 2018-12-31 | $145.32M 10-K · filed 2020-03-03 | |
| 2018-09-30 | $162.86M 10-Q · filed 2018-11-08 | |
| 2018-06-30 | $175.93M 10-Q · filed 2018-08-09 | |
| 2017-12-31 | $52.50M 10-K · filed 2019-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |